High‐grade B‐cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBL‐DH/TH) comprise ∼8% of tumors with diffuse large B‐cell lymphoma (DLBCL) morphology [1] and is associated with poor outcome after standard R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy [2]. Here, BCL2 is linked to diffuse large B-cell lymphoma.